Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. The evolution of tumor mutation burden as an immunotherapy biomarker. Major studies that are important in the ... Figure 1. The evolution of.

Published byBuddy Sharp Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. The evolution of tumor mutation burden as an immunotherapy biomarker. Major studies that are important in the ... Figure 1. The evolution of."— Presentation transcript:

1 Figure 1. The evolution of tumor mutation burden as an immunotherapy biomarker. Major studies that are important in the ... Figure 1. The evolution of tumor mutation burden as an immunotherapy biomarker. Major studies that are important in the development of TMB as a biomarker are shown. Color coding indicates type of study. The studies are ordered as a function of time, with the year indicated in the timeline. ICB, immune checkpoint blockade; 1L, first line; 2L, second line; +, and others; I-O, immune-oncology agent; IPI, ipilimumab; NIVO, nivolumab; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; TMB, tumor mutational burden. 1. Snyder A et al. N Engl J Med 2014; 371(23): 2189– Rooney MS et al. Cell 2015; 160(1–2): 48– Rizvi NA et al. Science 2015; 348(6230): 124– Rosenberg JE et al. Lancet 2016; 387(10031): 1909– Kowanetz M et al. Poster presentation at ESMO Abstract 77P. 6. Kowanetz M et al. Oral presentation at WCLC Abstract Balar AV et al. Lancet 2017; 389(10064): 67– Seiwert TW et al. J Clin Oncol 2018; 36(suppl 5S; abstract 25). 9. Chalmers ZR et al. Genome Med 2017; 9(1): Zehir A et al. Nat Med 2017; 23(6): 703– Carbone DP et al. N Engl J Med 2017; 376(25): 2415– Galsky MD et al. Poster presentation at ESMO Abstract 848PD. 13. Gandara DR et al. Oral presentation at ESMO Abstract 1295O. 14. Fabrizio DA et al. Poster presentation at ESMO Abstract 102P. 15. Mok T et al. Poster presentation at ESMO Abstract 1383TiP. 16. Antonia SJ et al. Oral presentation at WCLC Abstract Riaz N et al. Cell 2017; 171(4): 934– Foundation Medicine. (11 December 2017, date last accessed). 19. US Food and Drug Administration. (1 December 2017, date last accessed). 20. Hellmann MD et al. N Engl J Med 2018, doi: /NEJMoa Forde PM et al. N Engl J Med 2018, doi: /NEJMoa Cristescu et al. Science 2018; 362(6411). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 30, Issue 1, 05 November 2018, Pages 44–56, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Target regions and sizes of four different hypothetical gene panels (P1–P4). Depending on the size and ... Figure 2. Target regions and sizes of four different hypothetical gene panels (P1–P4). Depending on the size and territory of the exome that is captured by P1–P4, respectively, TMB counts will differ. Other parameters, e.g. filtering of germline variants and cut points for allelic frequencies (blue circles), discussed in this review will influence TMB measurement further. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 30, Issue 1, 05 November 2018, Pages 44–56, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Mutations, neoantigens, and immune checkpoint blockade
Figure 3. Mutations, neoantigens, and immune checkpoint blockade. Somatic mutations can generate neopeptides that are ... Figure 3. Mutations, neoantigens, and immune checkpoint blockade. Somatic mutations can generate neopeptides that are presented by MHC molecules. Both inflamed and non-inflamed tumors, as well as PD-L1 positive or negative tumors, can respond to immune checkpoint blockade therapy. TMB, tumor mutation burden; MMR, mismatch repair. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 30, Issue 1, 05 November 2018, Pages 44–56, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4. Impact of TMB pan-cancer: percent of solid tumors with TMB ≥10 mut/Mb. Analysis of top 30 solid tumor types ... Figure 4. Impact of TMB pan-cancer: percent of solid tumors with TMB ≥10 mut/Mb. Analysis of top 30 solid tumor types selected from 104,814 total cases sorted by percent of cases with TMB ≥10 mut/Mb according to the Foundation Medicine database. TMB is defined as the number of somatic synonymous and non-synonymous base substitutions and indels divided by the region over which it was counted. Only cancer types with at least 100 total cases are reported. The average across all solid tumor types was 13.3%. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 30, Issue 1, 05 November 2018, Pages 44–56, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. The evolution of tumor mutation burden as an immunotherapy biomarker. Major studies that are important in the ... Figure 1. The evolution of."

Similar presentations

Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion
Figure 1. autoMLST workflow depicting placement and de novo mode

Figure 1. autoMLST workflow depicting placement and de novo mode
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.
Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.
Fig. 1 Mean change from baseline in ANC ± s. e

Fig. 1 Mean change from baseline in ANC ± s. e
Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

Similar presentations

Ads by Google